Treats major depressive disorder (MDD). ANDA 208200, held by Invagen Pharms. Vilazodone Hydrochloride.
As of Nov 16, 2026, ANDA 208200 (Vilazodone Hydrochloride), held by Invagen Pharms, was first approved by FDA on Dec 6, 2022, with 2 approved supplements and 0 published complete response letters.
Vilazodone hydrochloride is indicated for the treatment of major depressive disorder (MDD) in adults.
| Dec 6, 2022 | Original application | Approved | None posted |
| Apr 7, 2021 | Original application | Approved | None posted |
| Vilazodone Hydrochloride10MG · tablet;oral | Vilazodone Hydrochloride | Rx |
| Vilazodone Hydrochloride40MG · tablet;oral | Vilazodone Hydrochloride | Rx |
| Vilazodone Hydrochloride20MG · tablet;oral | Vilazodone Hydrochloride | Rx |
| Jan 3, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 3, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 6, 2022 | Original application | Approved | None posted |
| Apr 7, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters